{"id":"https://openalex.org/W4387769844","doi":"https://doi.org/10.1007/s40744-023-00605-6","title":"Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)","display_name":"Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)","publication_year":2023,"publication_date":"2023-10-19","ids":{"openalex":"https://openalex.org/W4387769844","doi":"https://doi.org/10.1007/s40744-023-00605-6","pmid":"https://pubmed.ncbi.nlm.nih.gov/37858007","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10654305"},"language":"en","primary_location":{"id":"doi:10.1007/s40744-023-00605-6","doi":"https://doi.org/10.1007/s40744-023-00605-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40744-023-00605-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40744-023-00605-6.pdf","source":{"id":"https://openalex.org/S4210196954","display_name":"Rheumatology and Therapy","issn_l":"2198-6576","issn":["2198-6576","2198-6584"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatology and Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s40744-023-00605-6.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058629132","display_name":"Hideto Kameda","orcid":"https://orcid.org/0000-0002-4330-5782","observed_orcids":["https://orcid.org/0000-0002-4330-5782"]},"institutions":[{"id":"https://openalex.org/I129634264","display_name":"Toho University","ror":"https://ror.org/02hcx7n63","country_code":"JP","type":"education","lineage":["https://openalex.org/I129634264"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hideto Kameda","raw_affiliation_strings":["Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan"],"raw_orcid":"https://orcid.org/0000-0002-4330-5782","affiliations":[{"raw_affiliation_string":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan","institution_ids":["https://openalex.org/I129634264"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072715595","display_name":"Kohei Hagimori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kohei Hagimori","raw_affiliation_strings":["Eli Lilly Japan K.K., Kobe, Hyogo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K., Kobe, Hyogo, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111197473","display_name":"Yoji Morisaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoji Morisaki","raw_affiliation_strings":["Eli Lilly Japan K.K., Kobe, Hyogo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K., Kobe, Hyogo, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039720530","display_name":"Thorsten Holzk\u00e4mper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thorsten Holzk\u00e4mper","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079937050","display_name":"Ayako Konomi","orcid":"https://orcid.org/0009-0001-6884-1557","observed_orcids":["https://orcid.org/0009-0001-6884-1557"]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Ayako Konomi","raw_affiliation_strings":["Eli Lilly Japan K.K., Kobe, Hyogo, Japan. konomi_ayako@lilly.com","Eli Lilly Japan K.K., Kobe, Hyogo, Japan"],"raw_orcid":"https://orcid.org/0009-0001-6884-1557","affiliations":[{"raw_affiliation_string":"Eli Lilly Japan K.K., Kobe, Hyogo, Japan. konomi_ayako@lilly.com","institution_ids":["https://openalex.org/I4210108315"]},{"raw_affiliation_string":"Eli Lilly Japan K.K., Kobe, Hyogo, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5020106035","display_name":"Hiroaki Dobashi","orcid":"https://orcid.org/0000-0003-2944-5583","observed_orcids":["https://orcid.org/0000-0003-2944-5583"]},"institutions":[{"id":"https://openalex.org/I201933988","display_name":"Kagawa University","ror":"https://ror.org/04j7mzp05","country_code":"JP","type":"education","lineage":["https://openalex.org/I201933988"]},{"id":"https://openalex.org/I4210135297","display_name":"Kagawa University Hospital","ror":"https://ror.org/033sspj46","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I201933988","https://openalex.org/I4210135297"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroaki Dobashi","raw_affiliation_strings":["Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan","institution_ids":["https://openalex.org/I201933988","https://openalex.org/I4210135297"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5079937050"],"corresponding_institution_ids":["https://openalex.org/I4210108315"],"apc_list":{"value":6850,"currency":"USD","value_usd":6850},"apc_paid":{"value":6850,"currency":"USD","value_usd":6850},"fwci":1.5678,"has_fulltext":true,"cited_by_count":8,"citation_normalized_percentile":{"value":0.82975149,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":97},"biblio":{"volume":"10","issue":"6","first_page":"1683","last_page":"1703"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.00860000029206276,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ixekizumab","display_name":"ixekizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/psoriatic-arthritis","display_name":"psoriatic arthritis","score":0.9629999995231628},{"id":"https://openalex.org/keywords/peripheral-arthritis","display_name":"peripheral arthritis","score":0.675000011920929},{"id":"https://openalex.org/keywords/il-17a-inhibition","display_name":"IL-17A inhibition","score":0.8320000171661377},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.8190000057220459},{"id":"https://openalex.org/keywords/severe-disease","display_name":"severe illness","score":0.4699999988079071},{"id":"https://openalex.org/keywords/acr-response-criteria","display_name":"ACR response criteria","score":0.625},{"id":"https://openalex.org/keywords/pasi-improvement","display_name":"PASI improvement","score":0.7120000123977661},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.746999979019165},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.3630000054836273},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.640999972820282},{"id":"https://openalex.org/keywords/c-reactive-protein","display_name":"C-reactive protein","score":0.5910000205039978},{"id":"https://openalex.org/keywords/health-assessment-questionnaire","display_name":"Health Assessment Questionnaire","score":0.6240000128746033}],"concepts":[{"id":"https://openalex.org/C2779745271","wikidata":"https://www.wikidata.org/wiki/Q13574436","display_name":"Ixekizumab","level":5,"score":0.9526800513267517},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9100213646888733},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.8471407890319824},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.6695912480354309},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.651373028755188},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.6166842579841614},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5947188138961792},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.49195095896720886},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.4319915473461151},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.4140820801258087},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.3647616505622864},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22708410024642944},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.09634432196617126},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.053211212158203125},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.05098268389701843},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1007/s40744-023-00605-6","doi":"https://doi.org/10.1007/s40744-023-00605-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40744-023-00605-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40744-023-00605-6.pdf","source":{"id":"https://openalex.org/S4210196954","display_name":"Rheumatology and Therapy","issn_l":"2198-6576","issn":["2198-6576","2198-6584"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatology and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10654305","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10654305","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10654305/pdf/40744_2023_Article_605.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatol Ther","raw_type":"Text"},{"id":"pmid:37858007","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37858007","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatology and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:7a836e55396f4d16b31cc275841b7d4d","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/7a836e55396f4d16b31cc275841b7d4d","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Rheumatology and Therapy, Vol 10, Iss 6, Pp 1683-1703 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1007/s40744-023-00605-6","doi":"https://doi.org/10.1007/s40744-023-00605-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40744-023-00605-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40744-023-00605-6.pdf","source":{"id":"https://openalex.org/S4210196954","display_name":"Rheumatology and Therapy","issn_l":"2198-6576","issn":["2198-6576","2198-6584"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Rheumatology and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320333624","display_name":"Eli Lilly Japan","ror":"https://ror.org/01sv7f575"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4387769844.pdf","grobid_xml":"https://content.openalex.org/works/W4387769844.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W1967769016","https://openalex.org/W2055139776","https://openalex.org/W2109955020","https://openalex.org/W2148983798","https://openalex.org/W2149118348","https://openalex.org/W2154464235","https://openalex.org/W2171889601","https://openalex.org/W2512436288","https://openalex.org/W2620369605","https://openalex.org/W2724955338","https://openalex.org/W2773179393","https://openalex.org/W2883072230","https://openalex.org/W2890774149","https://openalex.org/W2944964876","https://openalex.org/W2975383698","https://openalex.org/W2991150004","https://openalex.org/W3004779610","https://openalex.org/W3027539208","https://openalex.org/W3032589454","https://openalex.org/W3098733875","https://openalex.org/W3208988466","https://openalex.org/W3216161603","https://openalex.org/W4200115039","https://openalex.org/W4211250344","https://openalex.org/W4241915332","https://openalex.org/W4281788390","https://openalex.org/W4307066750","https://openalex.org/W4309047198"],"related_works":["https://openalex.org/W4399177370","https://openalex.org/W2773179393","https://openalex.org/W3097362839","https://openalex.org/W2899230583","https://openalex.org/W2550837574","https://openalex.org/W3108326387","https://openalex.org/W2799735719","https://openalex.org/W2800009929","https://openalex.org/W2909339384","https://openalex.org/W2753742685"],"abstract_inverted_index":{"INTRODUCTION:":[0],"The":[1,267],"efficacy":[2,24],"and":[3,25,88,101,113,156,190,193,206,213,221,264],"safety":[4,26,223,242,268,279],"of":[5,15,27,34,67,143,225,235,254,281],"ixekizumab,":[6],"an":[7],"anti-interleukin-17A":[8],"antibody,":[9],"in":[10,29,168,227,259,261,270],"patients":[11,126,247],"with":[12,42,71,131,164,233,239,248,256,276],"severe":[13,72,122,170,229,249,272],"symptoms":[14],"psoriatic":[16,73,81,184,250],"arthritis":[17,74,90,185],"are":[18],"largely":[19],"unexplored.":[20],"We":[21],"report":[22],"the":[23,35,69,78,121,140,169,222,228,236,271,277],"ixekizumab":[28,44,132,150,154,226,257],"a":[30],"post":[31],"hoc":[32],"analysis":[33,66],"SPIRIT-P1":[36],"trial.":[37],"METHODS:":[38],"Patients":[39],"were":[40,166,231],"treated":[41,130],"placebo,":[43],"80":[45],"mg":[46,58],"every":[47],"2":[48],"weeks":[49,53,253],"(Q2W)":[50],"or":[51,55,97],"4":[52,95],"(Q4W),":[54],"adalimumab":[56],"40":[57],"Q2W":[59],"for":[60,149,153,158,172,183],"24":[61,252],"weeks.":[62],"In":[63,120,246],"this":[64],"subgroup":[65],"SPIRIT-P1,":[68],"population":[70,171,230,273],"was":[75,109,274],"defined":[76],"using":[77,198],"modified":[79],"composite":[80],"activity":[82,181,189,196],"index":[83,182],"total":[84],"score":[85,91,197],">":[86],"7":[87],"peripheral":[89],"=":[92],"3":[93],"(>":[94],"tender":[96],"swollen":[98],"joint":[99,112,263],"count":[100],"\u2265":[102],"0.5":[103],"Health":[104],"Assessment":[105],"Questionnaire-Disability":[106],"Index).":[107],"Efficacy":[108,219],"measured":[110],"by":[111],"skin":[114,265],"endpoints":[115],"including":[116],"disease":[117,180,188,195],"progression.":[118],"RESULTS:":[119],"population,":[123,238],"significantly":[124],"more":[125],"(p":[127,216],"\u2264":[128,217],"0.001)":[129],"than":[133],"placebo":[134,165],"achieved":[135],"20%":[136],"improvement":[137],"according":[138],"to":[139],"American":[141],"College":[142],"Rheumatology":[144],"criteria":[145],"(ACR":[146],"20):":[147],"63.3%":[148],"Q4W,":[151],"60.4%":[152],"Q2W,":[155],"24.5%":[157],"placebo.":[159],"Statistically":[160],"greater":[161],"responses":[162],"compared":[163],"observed":[167],"ACR":[173,175,177],"50,":[174],"70,":[176],"core":[178],"set,":[179],"(DAPSA)":[186],"low":[187],"DAPSA":[191],"remission,":[192],"28-joint":[194],"C-reactive":[199],"protein,":[200],"as":[201,203],"well":[202],"Psoriasis":[204],"Area":[205],"Severity":[207],"Index":[208],"(PASI)":[209],"75,":[210],"PASI":[211,214],"90,":[212],"100":[215],"0.001).":[218],"findings":[220],"profile":[224,269,280],"consistent":[232,275],"those":[234],"overall":[237],"no":[240],"new":[241],"concerns":[243],"identified.":[244],"CONCLUSIONS:":[245],"arthritis,":[251],"treatment":[255],"resulted":[258],"improvements":[260],"both":[262],"symptoms.":[266],"established":[278],"ixekizumab.":[282],"TRIAL":[283],"REGISTRATION:":[284],"ClinicalTrials.gov":[285],"identifier,":[286],"NCT01695239.":[287]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2023-10-20T00:00:00"}